Regatta Capital Group LLC Has $367,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Regatta Capital Group LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 7.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 14,497 shares of the biopharmaceutical company’s stock after selling 1,097 shares during the quarter. Regatta Capital Group LLC’s holdings in Pfizer were worth $367,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the 4th quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the 4th quarter worth approximately $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $23.36 on Monday. The business’s 50 day simple moving average is $22.95 and its two-hundred day simple moving average is $25.00. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $132.81 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.82 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.36%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.